CAR T Cells Beyond Cancer: Hope for Immunomodulatory Therapy of Infectious Diseases

Michelle Seif, Hermann Einsele and Jürgen Löffler*

Department of Internal Medicine II, University Hospital Wuerzburg, Wuerzburg, Germany

Infectious diseases are still a significant cause of morbidity and mortality worldwide. Despite the progress in drug development, the occurrence of microbial resistance is still a significant concern. Alternative therapeutic strategies are required for non-responding or relapsing patients. Chimeric antigen receptor (CAR) T cells has revolutionized cancer immunotherapy, providing a potential therapeutic option for patients who are unresponsive to standard treatments. Recently two CAR T cell therapies, Yescarta® (Kite Pharma/Gilead) and Kymriah® (Novartis) were approved by the FDA for the treatments of certain types of non-Hodgkin lymphoma and B-cell precursor acute lymphoblastic leukemia, respectively. The success of adoptive CAR T cell therapy for cancer has inspired researchers to develop CARs for the treatment of infectious diseases. Here, we review the main achievements in CAR T cell therapy targeting viral infections, including Human Immunodeficiency Virus, Hepatitis C Virus, Hepatitis B Virus, Human Cytomegalovirus, and opportunistic fungal infections such as invasive aspergillosis.

Keywords: infectious diseases, mAb engineering, CAR T cells, HIV, HCV, CMV, invasive aspergillosis, HBV

INTRODUCTION

Viral and opportunistic fungal infections represent a major threat to chronically infected individuals and immunocompromised patients. Despite the availability of antifungal and antiviral drugs, the mortality rate is still significant in high-risk patients (1–3). Current anti-viral treatments fail to cure chronic viral infections (caused by, e.g., HIV, HBV, and HCV) due to the viral-reservoir composed of infected cells that can stay latent for several years and would restart producing infectious virus at any time (4, 5) and the occurrence of resistance (6, 7). Therapies providing long term control or able to eradicate the viral-reservoir are required.

Pathogen-specific effector T cells play a crucial role in the control of acute viral and fungal infections in immunocompetent individuals (8–12), making adoptive T cell therapy an attractive alternative to currently used anti-infectious therapies. Pathogen-specific T cells occur in low frequencies in the patient's blood, making them difficult to isolate and expand. Moreover, they have exhausted phenotypes and might be rendered inefficient by viral escape mutation mechanisms lowering the major histocompatibility complex (MHC) or mutating the targeted epitope (10, 13–15). Thus, Chimeric antigen receptors (CARs) T cells present an attractive alternative.

CAR T cells are considered as a major scientific breakthrough and an important turning point in cancer immunotherapy (16), especially in the treatment of B cell malignancies. Recently, the US Food and Drug Administration (FDA) then the European Commission have approved two CAR T-cell products, Kymriah® (Novartis) and Yescarta® (Kite Pharma/ Gilead) for the treatment of B-cell precursor acute lymphoblastic leukemia and aggressive B-cell lymphoma, respectively.
CAR T cells are described as having the targeting specificity of a monoclonal antibody combined with the effector functions of a cytotoxic T cell (17). They offer potential advantages over pathogen-specific T cells, the CAR allows antigen recognition independent of the MHC and can be designed to specifically target the conserved and essential epitopes of the antigen, which allows them to overcome pathogen escape mechanisms.

Few anti-infectious CARs were described in the literature so far, most of them targeting HIV. Here we review the progress and discuss the remaining challenges of making CAR T cell therapy a reality for individuals suffering from infectious diseases. The main anti-infectious CAR constructs are summarized in Table 1.

**CAR T CELLS**

CARs are synthetic receptors composed of a targeting element linked by a spacer to a transmembrane domain followed by an intracellular signaling domain. The targeting element is usually, but not exclusively composed by a single-chain variable fragment (scFv) (17). The spacer constitutes mainly of a full-length Fc receptor of an IgG (Hinge-CH2-CH3) or shorter parts like the Hinge region only or Hinge-CH2 (37–40). Furthermore, parts of the extracellular domains of CD28 and CD8α were used as spacers (41, 42). Several transmembrane domains were used to anchor the receptor on the surface of a T cell, mainly derived from CD28, CD8α, or CD4 (42–44). The signaling domain consists of the intracellular part of CD3ζ from the TCR complex (45). Over the years, in order to improve the CAR functionality and persistence, several generations of CARs have been established differing in their intracellular signaling (17). First-generation CARs mediated T-cell activation only through the CD3ζ complex (45, 46). Second-generation CARs include an intracellular costimulatory domain, mainly CD28 or 4-1BB, leading to an enhanced expansion, and functionality (43, 47–52). These second-generation receptors are the origin of the recently approved CAR T-cell therapies (53). Third-generation CARs combine two costimulatory domains, mainly CD28, and 4-1BB (54). Finally, fourth-generation CARs, also called TRUCKs (T-cells redirected for universal cytokine-mediated killing), emerged, including an additional transgene for inducible cytokine secretion upon CAR activation [mainly IL-12 (55)]. Several other strategies for minimizing toxicity and enhancing versatility and control of CAR T cells were reviewed by others (17, 56).

**CD4 Based CARs**

The concept of CAR T cells was initially described in the 90th when the cytotoxic T cells specificity was redirected toward HIV infected cells. The first CAR was specific for HIV envelope protein (Env) using the CD4 receptor as a targeting element fused to the CD3ζ chain for intracellular signaling (CD4tCAR) (61, 62). Clinical trials with the CD4tCAR showed that the concept is feasible and safe, but failed to reduce HIV viral burden permanently (63–66).

To improve the CAR T cell activity and persistence, CD4tCAR was re-engineered into second-generation and third-generation CARs. While CAR T cells containing CD28 costimulatory domain promoted higher cytokine production and better control over HIV replication in vitro, the 4-1BB containing CARs were more potent in controlling HIV infection in vivo. When compared to first-generation CAR T cells, second-generation CAR T cells were more potent at suppressing HIV replication in vitro. Furthermore, in a humanized mouse model of HIV infection, they preserved the CD4+ T cell count, reduced HIV burden, and expanded to a greater extent than first-generation CAR T cells (20).

However, it was shown that CD4 based CARs render the CAR T cells susceptible to HIV infection (18, 25). To overcome this limitation, CD4tCAR was equipped with either a viral fusion inhibitor (C46 peptide) (18) or small hairpin RNAs to knock down HIV-1 co-receptor CC-chemokine receptor 5 (CCR5) and degrade viral RNA (19). Both methods successfully rendered CD4tCAR T resistant to HIV infection and conferred them a long persistence and proper control of HIV infection in vivo (18, 19).

Moreover, several genome editing techniques were used to knock out CCR5 in T cells to confer them permanent resistance to HIV infection (67). These include the use of ZFNs (Zinc-finger nucleases) (68), which showed promising results in clinical trials (NCT00842634, NCT01044654, NCT01252641), TALEN (Transcription activator-like nucleases) (69, 70), and CRISPR-CAS 9 (71) in preclinical studies. These endonucleases were already used to produce universal CAR T cells by knocking down the TCR (72–77). It would be useful to test them to knock down CCR5 in HIV-CAR T cells.

**scFvs Based CARs**

To avoid using the CD4 as targeting element, novel CARs of several generations were designed using single-chain variable fragments (scFv) derived from broadly neutralizing antibodies (bNabs) targeting Env.

Targets included the CD4-binding site, several antigens of glycoprotein 120 (gp120), the membrane-proximal region of gp41, the mannose-rich region, and variable glycan regions (20, 21, 24, 78).

Second-generation CARs for the different targets enabled the CAR T cells to kill HIV-1-infected cells. However, their antiviral activity was variable according to the virus strain (78). Second-generation anti-glycan CARs, in combination with CCR5 ablation, provided better control of viral replication than the CAR alone (24).

First-generation anti-gp120 CARs induced efficient activation and cytokine secretion by the gene-modified T cells and mediated
TABLE 1 | CAR design of the most promising anti-infectious CAR-T cells.

| Pathogen                  | Targeted antigen                  | Targeting element       | Spacer       | Transmembrane domain | Costimulatory domain | Extra modification      | References |
|---------------------------|-----------------------------------|-------------------------|--------------|-----------------------|----------------------|-------------------------|------------|
| HIV                       | CD4 binding site on gp-120        | CD4                     | n.a.         | CD4                   | n.a.                 | C46 peptide             | (18)       |
|                           | CD4 binding site on gp-120        | CD4                     | n.a.         | CD4                   | n.a.                 | CCR5 sh 1005; sh 516    | (19)       |
|                           | CD4 binding site on gp-120        | CD4                     | n.a.         | CD8α                  | CD28                 | CD28 or 4-1BB            | (20)       |
|                           | CD4 binding site on gp-120        | CD4                     | n.a.         | CD28                 | CD28                 | CD28-4-1BB               | (21)       |
|                           | CD4 binding site on gp-120        | CD4                     | n.a.         | CD28                 | CD28                 | aa52                | (22)       |
| Env/gp120 glycans         | CD4/CRD                           | CD48 hinge              | CD28         | CD28                 | CD28                 | CD28                  | (23)       |
| V1/V2 glycan loop          | PGT145-scFv                        | CD8α Hinge              | CD28         | CD28                 | CD28                 | CD28                  | (24)       |
| CD4-induced epitope on   | 17b-scFv/CD4                       | CD8α Hinge              | CD28         | CD28                 | CD28                 | CD28                  | (25)       |
| gp120/CD4 binding site    |                                   |                        |              |                       |                      |                        |            |
| CD4-induced epitope on   | mD1.22-GmS-m38.4                   | CD8                    | CD8          | CD8                  | CD8                  | 4-1BB                 | (26)       |
| HBV                       | HBV surface protein                 | C8-scFv                 | IgG1 Fc      | CD28                 | CD28                 | CD28                  | (27–29)    |
| HBV surface antigen       | 19.79.6-scFv                       | IgG4 Fc mutated         | CD28         | CD28                 | CD28                 | CD28                  | (30)       |
| HCV                       | HCV E2 glycoprotein                | e137-scFv               | Ig3 Fc       | CD28                 | CD28                 | CD28                  | (31)       |
| CMV                       | Glycoprotein B                     | 27-287-scFv             | IgG Hinge    | CD28                 | CD28                 | CD28                  | (32–34)    |
|                           | Virally encoded FcRs               | IgG1 or IgG4 Fc mutated | n.a.         | CD28                 | CD28                 | CD28                  | (35)       |
| Aspergillus fumigatus     | β-glucan                           | Dectin 1                | IgG4 Fc mutated | CD28                 | CD28                 | CD28                  | (36)       |

lysis of envelope-expressing cells and HIV-1-infected CD4+ T-lymphocytes in vitro (22). Third generation anti-gp120 CAR-T cells were more efficient than CD4 based CARs in lysing gp120 expressing cells in vitro. Furthermore, their interaction with cell-free HIV did not result in their infection. More importantly, they efficiently induced cytolysis of the reactivated HIV reservoir isolated from infected individuals. Thus, anti-gp120 third-generation CAR T cells might be a suitable candidate for therapeutic approaches aiming to eradicate the HIV reservoir (21).

However, one major drawback to developing scFvs-based CAR T cell therapy is the HIV viral escape mutation mechanism that can abrogate the antibody-binding site and render the CAR T cell therapy inefficient.

Bi- and tri-specific CARs

In order to overcome the HIV mutation escape mechanism, bi-and tri-specific CAR-expressing T cells targeting up to three HIV antigens were designed to increase the specificity and affinity.

The CD4 segment was fused with an scFv specific for a CD4-induced epitope on gp120 (25) or the carbohydrate recognition domain (CRD) of a human C-type lectin binding to conserved glycans on Env (23). The CD4-anti gp120 scFv bispecific CAR had better suppressive activity against HIV than the CD4 alone. CD4-mannose binding lectin (MBL) CARs showed the best potency when compared to both CD4 alone and CD4-anti gp120 (23). However, since C-type lectins can bind glycans which are not specific for HIV infected cells and can be associated with healthy cells, off-targets cannot be excluded.

More recently, T cells were engineered with up to three functionally distinct HIV envelope-binding domains to form bispecific and tri-specific targeting anti-HIV CAR-T cells. These cells carry two distinct CARs expressed on one T cell or one CAR having two targeting elements linked together. Targets included CD4-binding site on HIV gp120 and CD4-induced (CD4i) epitope on gp120 near the co-receptor binding site. Tri-specific CARs expressed the C46 peptide, which inhibits HIV viral fusion and thus can prevent the infection of CAR T cells. Bi-and tri-specific CAR T cells showed potent in vitro and in vivo anti-HIV effects, they efficiently killed HIV-infected cells in a humanized mouse model while protecting the CAR- T cells from infection (26).

Despite all the challenges faced, anti-HIV CAR T cell therapy made much progress toward enhancing the CAR T cell antiviral activity, protecting CAR T cells from HIV infection, and overcoming HIV escape mechanisms. Currently, at least two clinical trials are ongoing for latent reservoir eradication, one using a modified bNAb-based CAR-T cell therapy (NCT03240328) and one using CD4-based CAR-T cell therapy with CCR5 ablation (NCT03617198).

CAR T CELLS SPECIFIC FOR HEPATITIS B VIRUS (HBV)

Some preclinical studies are focusing on engineering second-generation CAR T cells to cure chronic hepatitis B and prevent the development of hepatocellular carcinoma (HCC). Cytotoxic T cells were redirected toward HBV surface and secreted antigens.
Second generation CAR T cells were designed to target HBV-surface proteins S and L, which are expressed continuously on the surface of HBV replicating cells. S and L specific CAR T cells were able to recognize soluble HBsAg and HBsAg-positive hepatocytes in vitro and subsequently secret IFNγ and IL-2. S-CAR T cells were activated faster and secreted higher cytokine levels than L-CAR T cells. This might be due to the higher expression of the S-protein on the surface of viral and subviral particles when compared with the L-protein (27).

Furthermore, both CAR T cells were able to lyse HBV transfected cells as well as selectively eliminated HBV-infected primary hepatocytes. However, even after the elimination of HBV-infected hepatocytes, HBV core protein and HBV rcDNA remained detectable. It is most probably because HBV rcDNA is localized in viral capsids and thus protected from caspase-activated DNases (27). The S-CAR construct was tested in vitro in an immune-competent HBV transgenic mouse model. CD8⁺ mouse T cells expressing the human S-CAR localized to the liver and effectively reduced HBV replication, causing only transient liver damage. Furthermore, contact of CAR T cells with circulating viral antigen did not lead to their functional exhaustion or excessive liver damage. However, the survival of the CAR T cells was limited due to the immune response triggered by the human CAR (28). In an immunocompetent mouse model tolerized with a signaling-deficient S-CAR, S-CAR T cells persisted and showed long-lasting antiviral effector function (29). However, the use of a transgene instead of cccDNA to transcribe HBV makes these mouse models unsuitable to judge whether S-CAR T cells can cure HBV infection (28, 29).

More recently, other novel second-generation CARs targeting HBsAg were designed with different spacer length. Only HBs-Ag-CAR T-cells equipped with a long spacer (HBs-G4m-CAR) recognized HBV-positive cell lines and HBsAg particles in vitro and subsequently produced significant amounts of IFNγ, IL-2, and TNF-α. However, HBs-G4m-CAR T cells were not capable of killing HBV-positive cell lines in vitro. This might be due to HBsAg particles produced by HBV-positive cells that can bind to HBs-G4m-CAR T-cells and potentially inhibit CAR-T targeting or killing of infected cells. In a humanized HBV-infected mouse model, adoptive transfer of HBsAg-CAR T-cells led to the accumulation of the cells in the liver and an important reduction in plasma HBsAg and HBV-DNA levels. Furthermore, the absence of HBV core expression in a portion of human hepatocytes and the unchanged plasma human albumin levels indicated HBV clearance without destruction of the infected hepatocytes. However, no complete elimination of HBV was observed. Despite this limitation, HBs-G4m-CAR T cells had superior anti-HBV activity than HBV entry inhibitors (30).

These studies showed promising results; a direct comparison of S-CAR T cell and HBsAg-CAR T-cell would be interesting to test. Furthermore, a better mouse model more representative of the actual infection should be used to evaluate the CAR activity in vivo. Finally, combination therapy using CAR T-cells with reverse transcriptase inhibitors or hepatitis B immunoglobulin might be required to have better control of the HBV infection.

**CAR T CELLS SPECIFIC FOR HEPATITIS C VIRUS (HCV)**

Very recently, the first two CARs targeting HCV were designed based on a broadly cross-reactive and cross-neutralizing human monoclonal antibody specific for a conserved epitope of the HCV E2 glycoprotein (HCV/E2). Anti-HCV CAR T cells showed good anti-viral activity and lysed HCV/E2-transfected as well as HCV-infected target cells (31).

This study showed that the concept of CAR T cells might also be suitable for the treatment of HCV. The described CAR should be evaluated in vivo in a suitable animal model. Furthermore, since HCV/E2 is the main target of the host immune response and is consequently very susceptible to mutations (32), targeting other conserved, and essential antigens might also be of interest.

**CAR T CELLS SPECIFIC FOR HUMAN CYTOMEGALOVIRUS (CMV)**

The first CAR targeting CMV was described in 2010 based on the anti-gB antibody. Second generation gB CAR T cells were activated when co-cultured with CMV-infected cells and secreted TNFα and IFNγ and subsequently inhibited CMV replication in infected cells (33–35). Moreover, they eliminated gB transfected cells (33) but were not always able to lyse infected cells, especially at later stages of the replication cycle. This might be due to HCMV-encoded anti-apoptotic proteins that are known to prevent the suicide of infected host cells (34, 35). This CAR T cell therapy was not tested in vivo due to the few sequence similarities between the murine CMV gB protein and the human one. An appropriate mouse model using a recombinant MCMV expressing HCMV-gB should be developed (33).

In a later study, it was shown that the long spacer (CH2–CH3 Fc domain from IgG1) usually used in CAR preparation could bind to virally encoded Fc binding receptors on the surface of infected cells and act as a receptor for CMV. The mutated form of the spacer is only recognized by viral FcRs and not the human ones. In this way, the long spacer can act as a receptor for CMV infected cells (35).

The gB-CAR with long and short spacer should be further tested in vivo in an appropriate animal model. More targeting elements should be tested. Finally, the combination of new targeting elements with a long spacer might confer a bispecific targeting of CMV infected cells.

**CAR T CELLS SPECIFIC FOR EPSTEIN-BARR VIRUS (EBV)**

To target Epstein-Barr virus (EBV) associated malignancies, a second-generation CAR specific for the EBV latent membrane protein 1 (LMP1) was described. EBV-CAR T cells were activated in vitro in co-culture with nasopharyngeal carcinoma cells overexpressing LMP1.
and subsequently produced IFN-γ and IL-2. Intra-tumoral injection of EBV-CAR T cells in a xenograft mouse model having tumors overexpressing LMP1 reduced tumor growth (79).

CAR-T cell therapy for solid tumors is still facing many challenges, like the inability to reach the tumor and survive in the tumor microenvironment. These challenges and the developed strategies to overcome them were reviewed by others (80).
CAR T CELLS SPECIFIC FOR Aspergillus fumigatus

A second-generation CAR using the extracellular domain of Dectin-1 as targeting element called D-CAR was designed to target Aspergillus fumigatus. Dectin 1 is a C-type lectin receptor specific for β-glucan, a motif expressed on the surface of many fungi (81). D-CAR T cells were activated by β-glucan and subsequently secreted IFNγ and induced hyphal damage in vitro. In an immunocompromised invasive aspergillosis mouse model, D-CAR T cells reduced the fungal burden (36).

This study suggested that the application of CAR T cells might extend beyond cancer and chronic viral infections to acute fungal infections. Although promising results were shown for D-CAR T cells, Dectin 1 might not be the best targeting element to redirect the T cell specificity toward Aspergillus fumigatus. Since β-glucans are not specific for Aspergillus fumigatus but rather a broad range of commensals and pathogenic microorganisms, off-target activity of the CAR T cells cannot be excluded (82). Using scFvs derived from fungal specific antibodies might provide better specificity and activity of the CAR. Moreover, strategies to significantly shorten the CAR T cell preparation time (currently time from leukapheresis to infusion of the CART product can take up to 3–4 weeks (83)) will be essential to allow their clinical use for acute infections.

CONCLUSION AND PERSPECTIVES

CAR T-cell therapy has gained much interest since its clinical application was approved for cancer immunotherapy. Relying on the knowledge accumulated on CAR T cell engineering in cancer research, many efforts are being made toward developing similar therapies for patients affected by chronic viral and acute invasive fungal infections. While targets are more precise and unique to the pathogen, making it easier to avoid off-targets, pathogen escape mechanisms, and reservoirs are still major obstacles.

Several CARs targeting infectious diseases have been described; the most relevant ones are summarized in Figure 1 and Table 1. Tremendous progress was made in anti-HIV CAR T cell therapy, which reached now clinical trials. CAR T cells targeting other viruses such as HBV, HCV, CMV, and opportunistic fungi are still in their early pre-clinical testing. So far, promising data were observed, providing a proof of concept of CAR T cell application. Nevertheless, considerable optimization work is still required regarding the safety and efficacy of the constructs. More targets should be evaluated in vitro and in vivo in relevant animal models.

AUTHOR CONTRIBUTIONS

MS wrote the manuscript. JL and HE reviewed and edited the manuscript. All authors approved the manuscript for publication.

FUNDING

This work was funded by the Bundesministerium für Bildung und Forschung (BMBF) (Infect Control 2020—consortium ART4Fun; subproject 2 to HE), the Deutsche Forschungsgemeinschaft (Collaborative Research Center/Transregio 124 Pathogenic fungi and their human host: Networks of interaction—FungiNet; project A2 to HE and JL), and Deutsche Forschungsgemeinschaft (Forschergruppe 2830, Advanced Concepts in Cellular Immune Control of Cytomegalovirus, project 09 to HE).

REFERENCES

1. Heinz WJ, Vehreschild JJ, Buchheidt D. Diagnostic work up to assess early response indicators in invasive pulmonary aspergillosis in adult patients with haematological malignancies. Mycoses. (2019) 62:486–93.doi: 10.1111/myc.12860
2. Green ML. CMV viral load and mortality after hematopoietic cell transplantation: a cohort study in the era of preemptive therapy. Lancet Haematol. (2016) 3:e119–27.doi: 10.1016/S2352-3026(15)00289-6
3. Teira P, Battiwalla M, Ramanathan M, Barrett AJ, Ahn KW, Chen M, et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. (2016) 127:2427–38.doi: 10.1182/blood-2015-11-679639
4. Bongiovanni M, Adorni F, Casana M, Tordato F, Tincati C, Cicconi P, et al. Subclinal hypothyroidism in HIV-infected subjects. J Antimicrob Chemother. (2016) 71:216–23.doi: 10.1093/jac/dkw375
5. Wong JK, Hezareh M, Günthard HF, Havlir DV, Ignacio Gastroenterology. (2016) 125:455–63.doi: 10.1172/JCI80566
6. Margeridon-Thermet S, Shafer RW. Comparison of the mechanisms of drug resistance among HIV, hepatitis B, and hepatitis C. Viruses. (2010) 2:2696–739.doi: 10.3390/v2122696
7. Neumann-Haefelin C, Thimme R. Adaptive immune responses in hepatitis C virus infection. Curr Top Microbiol Immunol. (2010) 369:23–62.doi: 10.1007/978-3-642-27340-7_10
8. Klenerman P, Ozenius A. T cell responses to cytomegalovirus. Nat Rev Immunol. (2016) 16:367–77.doi: 10.1038/nri.2016.38
9. Maini MK, Boni C, Ogg GS, King AS, Reignat S, Chun Kyon Lee, et al. Direct ex vivo analysis of hepatitis B virus-specific CD8+ T cells associated with the control of infection. J Clin Invest. (2016) 126:455–63.doi: 10.1172/JCI80566
10. Kumaresan PR, da Silva TA, Kontoyiannis DP. Methods of controlling invasive fungal infections using CD8+ T cells associated with the control of infection. Gastroenterology. (1999) 117:1386–96.doi: 10.1016/S0016-5085(99)70289-1
11. Iijima S, Lee Y-J, Ode H, Arold ST, Kimura N, Yokoyama M, et al. A Non-canonical mu-1A-binding motif in the N terminus of HIV-1 nef determines its ability to downregulate major histocompatibility complex class I in T lymphocytes. J Virol. (2012) 86:3944–51.doi: 10.1128/JVI.0257-11
12. Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol. (2007) 81:4215–25.doi: 10.1128/JVI.02844-06
17. Subklewe M, Von Bergwelt-Baildon M, Humpe A. Chimeric antigen receptor T cells: a race to revolutionize cancer therapy. Transfus Med Hemother. (2019) 46:15–24.doi: 10.1159/000496870

18. Zhen A, Peterson CW, Carrillo MA, Reddy SS, Youn CS, Lam BB, et al. Long- 
32. Sautto G, Tarr AW, Mancini N, Clementi M. Structural and 
31. Sautto GA, Wisskirchen K, Clementi N, Castelli M, Diotti RA, G raf 
30. Kruse RL, Shum T, Tashiro H, Barzi M, Yi Z, Whitten-Bauer C, et a l. Chimeric antigen receptor T cells in hepatitis B virus surface proteins eliminate infected hepatocytes. Gastroenterology. (2008) 134:239–47.doi: 10.1053/j.gastro.2007.11.002

29. Festag MM, Festag I, Fräkle SP, Assen T, Sacherl J, Schreiber S, et al. Evaluation of a fully human, hepatitis B virus-specific chimeric antigen receptor in an immunocompetent mouse model. Mol Ther. (2019) 27:947– 
59.doi: 10.1016/j.mther.2019.02.001

28. Krebs K, Böttner N, Huang LR, Chmielewski M, Azrberger S, Gasteiger G, et al. T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice. Gastroenterology. (2013) 145:436–65.doi: 10.1053/j.gastro.2013.04.047

27. Kruse RL, Shum T, Tashiro H, Barzi M, Yi Z, Whitten-Bauer C, et al. HBsAg-redirected T cells exhibit antiviral activity in HBV-infected human liver chimeric mice. Cytotherapy. (2018) 20:697–705.doi: 10.1016/j.jcyt.2018. 02.002

26. Sautto GA, Wisskirchen K, Clementi N, Castelli M, Diotti RA, Graf J, et al. Chimeric antigen receptor (CAR)-engineered t cells redirected against hepatitis C virus (HCV) E2 glycoprotein. Gut. (2016) 65:512– 
23.doi: 10.1136/gutjnl-2014-308316

25. Marchetti C, G渔民 A, Wisse N, Diotti RA, Graf J, et al. Chimeric antigen receptor (CAR) -engineered T cells redirected against hepatitis C virus E2 glycoprotein epitopes targeted by monoclonal antibodies. Clin Dev Immunol. (2013) 2013:450963.doi: 10.1155/2013/450963

24. Arzberger S, Gasteiger G, Halbritter J, et al. Chimeric antigen receptor T cells engineered with a cytomegalovirus-specific chimeric immunoreceptor. J Virol. (2010) 84:4083–8.doi: 10.1128/JVI.01517-09

23. Ghanem MH, Bolivar-Wagers S, Dey B, Hajduczki A, Vargas-Inchaustegui 
22. Masiero S, Del Vecchio C, Gavioli R, Mattiuzzo G, Micheli L, et al. T cell engineering by a chimeric T-cell receptor with antibody-type specificity for the HIV-1 gp120. Gene Ther. (2005) 12:299–310.doi: 10.1038/sj.gt.3302413

21. Liu B, Zou F, Lu L, Chen C, He D, Zhang X, et al. Chimeric antigen receptor T cells guided by the single-chain Fv of a broadly neutralizing antibody specifically and effectively eradicate virus reactivated from latency in CD4+ T lymphocytes isolated from HIV-1-infected individuals receiving suppressive combined antiretroviral therapy. J Virol. (2016) 90:69712– 
24.doi: 10.1128/JVI.00852-16

20. Masiero S, Del Vecchio C, Gavioli R, Mattiuzzo G, Micheli L, et al. Supraphysiologic control over HIV-1 replication mediated by CD8+ T cells expressing a re-engineered CD4-based chimeric antigen receptor. PLoS Pathog. (2017) 13:1–30.doi: 10.1371/journal.ppat.1006613

19. Leibman RS, Richardson MW, Ellebrecht CT, Maldini CR, Glover JA, Secreto 
18. Zhen A, Peterson CW, Carrillo MA, Reddy SS, Youn CS, Lam BB, et al. Long- 
17. Subklewe M, Von Bergwelt-Baildon M, Humpe A. Chimeric antigen receptor T cells: a race to revolutionize cancer therapy. Transfus Med Hemother. (2019) 46:15–24.doi: 10.1159/000496870

15. Kurktschiev PD, Carrillo MA, Reddy SS, Youn CS, Lam BB, et al. Dysfunctional CD8+ T cells in hepatitis B and C are characterized by a lack of antigen-specific T-bet induction. J Exp Med. (2014) 211:2047–59.doi: 10.1084/jem.20131333

14. Couzin-Frankel J. Cancer immunotherapy. Crit Rev Clin Lab Sci. (2016) 836:167–89.doi: 10.4168/crcl.2016.836.9.028909

13. Kurktschiev PD, Raziorrouh B, Schraut W, Backmund M, Wächtler M, Seif et al. CAR T Cells for Therapy of Infectious Diseases

12. Proff J, Walterskirchen K, Brey C, Geyerregger R, Full F, Ensser A, et al. Cytomegalovirus-infected cells resist T cell-mediated killing in an HLA-recognition independent manner. Front Microbiol. (2016) 7:1– 
15.doi:10.3389/fmicb.2016.00844

11. Kurktschiev PD, Raziorrouh B, Schraut W, Backmund M, Wächtler M, Seif et al. CAR T Cells for Therapy of Infectious Diseases

10. Proff J, Brey CU, Ensser A, Holter W, Lehner M. Turning the tables on cytomegalovirus: targeting viral Fc receptors by CARs containing mutated CH2 – CH3 IgG spacer domains. J Transl Med. (2018) 1– 
12.doi:10.1186/s12978-014-1934-x

9. Kurktschiev PD, Raziorrouh B, Schraut W, Backmund M, Wächtler M, Seif et al. CAR T Cells for Therapy of Infectious Diseases

8. Proff J, Brey CU, Ensser A, Holter W, Lehner M. Turning the tables on cytomegalovirus: targeting viral Fc receptors by CARs containing mutated CH2 – CH3 IgG spacer domains. J Transl Med. (2018) 1– 
12.doi:10.1186/s12978-014-1934-x

7. Kurktschiev PD, Raziorrouh B, Schraut W, Backmund M, Wächtler M, Seif et al. CAR T Cells for Therapy of Infectious Diseases

6. Proff J, Brey CU, Ensser A, Holter W, Lehner M. Turning the tables on cytomegalovirus: targeting viral Fc receptors by CARs containing mutated CH2 – CH3 IgG spacer domains. J Transl Med. (2018) 1– 
12.doi:10.1186/s12978-014-1934-x

5. Kurktschiev PD, Raziorrouh B, Schraut W, Backmund M, Wächtler M, Seif et al. CAR T Cells for Therapy of Infectious Diseases

4. Proff J, Brey CU, Ensser A, Holter W, Lehner M. Turning the tables on cytomegalovirus: targeting viral Fc receptors by CARs containing mutated CH2 – CH3 IgG spacer domains. J Transl Med. (2018) 1– 
12.doi:10.1186/s12978-014-1934-x

3. Kurktschiev PD, Raziorrouh B, Schraut W, Backmund M, Wächtler M, Seif et al. CAR T Cells for Therapy of Infectious Diseases

2. Proff J, Brey CU, Ensser A, Holter W, Lehner M. Turning the tables on cytomegalovirus: targeting viral Fc receptors by CARs containing mutated CH2 – CH3 IgG spacer domains. J Transl Med. (2018) 1– 
12.doi:10.1186/s12978-014-1934-x

1. Kurktschiev PD, Raziorrouh B, Schraut W, Backmund M, Wächtler M, Seif et al. CAR T Cells for Therapy of Infectious Diseases
50. Finney HM, Akbar AN, Lawson ADG. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR, chain. J Immunol. (2004) 172:104–13 doi: 10.4049/immunol.172.1.104

51. Porter D, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. (2011) 365:725–33. doi: 10.1056/NEJMoa1103849

52. van der stegen SJ, Hamieh M, Sadelain M. The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov. (2015) 14:499–509. doi: 10.1038/nrd4597

53. Salmikangas P, Kinsella N, Chamberlain P. Chimeric antigen receptor T-cells (CAR T-cells) for cancer immunotherapy – moving target for industry? Pharm Res. (2018) 35:1–8. doi: 10.1007/s11095-018-2436-z

54. Wang J, Jensen M, Lin Y, Sui X, Chen E, Lindgren CG, et al. Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Hum Gene Ther. (2007) 18:712–25. doi: 10.1089/hum.2007.028

55. Chmielewski M, Abken H. CAR T cells transform to trucsk: chimeric antigen receptor-receptorized T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer. Cancer Immunol Immunother. (2012) 61:1269–77. doi: 10.1007/s00262-012-1202-z

56. Fesnak AD, June CH, Levine BL. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer. (2016) 16:566–81. doi: 10.1038/nrc.2016.97

57. Maldini CR, Ellis GI, Riley JL. CAR T cells for infection, autoimmunity and allotransplantation. Nat Rev Immunol. (2018) 18:603–16. doi: 10.1038/s41577-018-0042-2

58. Wagner TA. Quarter century of Anti-HIV CAR T cells. (2015) 344:1173–8. doi: 10.1038/nrd4597

59. Liu B, Zhang W, Zhang H. Development of CAR-T cells for long-term eradication and surveillance of HIV-1 reservoir.Curr Opin Virol. (2019) 38:21–30. doi: 10.1016/j.coiv.2019.04.004

60. Kuhlmann AS, Peterson CW, Kiem HP. Chimeric antigen receptor-T cell approaches to HIV cure. Curr HIV AIDS. (2018) 13:446–53. doi: 10.1007/CO.10000000000485

61. Romeo C, Seed B. Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. Cell. (1991) 64:1037–46. doi: 10.1016/0092-8674(91)90327-U

62. Roberts MR, Qin L, Zhang D, Smith DH, Tran AC, Dull TJ, et al. Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors. Blood. (1994) 84:2878–89. doi: 10.1182/blood.V84.9.2878.bloodjournal942878

63. Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, Hege KM, et al. Decade-long safety and function of retroviral-modified HIV-1 resistant CD4+ T cells in chronic lymphoid leukemia. N Engl J Med. (2011) 365:725–33. doi: 10.1056/NEJMoa1103849

64. Walker RE, Bechtel CM, Natarajan V, Baseler M, Hege KM, et al. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol Ther. (2002) 5:788–97. doi: 10.1006/mthe.2002.0611

65. Kwarteng A, Ahuno ST, Kwakye-Nuako G. The therapeutic landscape of HIV-1 via genome editing. AIDS Res Ther. (2017) 14:1–16. doi: 10.1186/s12981-017-0157-8

66. Perez EE, Wang J, Miller JC, Jouveyen Y, Kim KA, Liu O, et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol. (2008) 26:808–16. doi: 10.1038/nbi1410

67. Mock U, MacHowicz R, Hauber I, Horn S, Abramowski P, Berdien B, et al. mRNA transfection of a novel TAL effector nuclease (TALEN) facilitates efficient knockout of HIV co-receptor CCR5. Nuclear Acids Res. (2015) 43:5560–71. doi: 10.1093/nar/gkv469

68. Perez EE, Wang J, Miller JC, Jouveyen Y, Kim KA, Liu O, et al. Multiplex genome-edited T-cell manufacturing platform for “off-the-shelf” adoptive T-cell immunotherapies. Cancer Res. (2015) 75:3853–64. doi: 10.1158/0008-5472.CAN-14-3321

69. Berdien B, Mock U, Atanackovic D, Fehse B. TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer. Gene Ther. (2014) 21:539–48. doi: 10.1038/gt.2014.26

70. Ren J, Liu X, Fang C, Jiang S, June CH, Zhao Y. Multiplex genome engineering to generate universal CAR T cells resistant to PD1 inhibition. Clin Cancer Res. (2013) 29:2255–66. doi: 10.1158/1078-0432.CCR-16-1300

71. Ren J, Zhang X, Liu X, Fang C, Jiang S, June CH, et al. A versatile system for rapid multiplex genome-edited CAR T cell generation. Oncotarget. (2017) 8:17002–11. doi: 10.18632/oncotarget.15218

72. Ali A, Kitchen SG, Chen ISY, Ng HL, Zack JA, Yang OO. HIV-1-specific chimeric antigen receptors based on broadly neutralizing antibodies. J Virol. (2016) 90:6999–7006. doi: 10.1128/JVI.00815-16

73. Tang X, Zhou Y, Li W, Tang Q, Chen R, Zhu J, et al. T cells expressing a LMPI-specific chimeric antigen receptor mediate antitumor effects against LMPI-positive nasopharyngeal carcinoma cells in vitro and in vivo. J Biomed Res. (2014) 28:468–75. doi: 10.7555/JBR.28.20140066

74. D’Alia MM, Zizzari GI, Sacchetti B, Pierielli L, Alimandi M. CAR-T cells: the long and winding road to solid tumors review-article. Cell Death Dis. (2018) 9:282. doi: 10.1038/s41419-018-0278-6

75. Bowman SM, Free SJ. The structure and synthesis of the fungal cell wall. BioEssays. (2006) 28:799–808. doi: 10.1002/bies.20441

76. Ilevy ID, Funari VA, Taylor KD, Nguyen Q, Reyes CN, Strom SP, et al. Interactions between commensal fungi and the C-type lectin receptor dectin-1 influence colitis. Science. (2012) 336:1314–7. doi: 10.1126/science.1212719

77. Buechner J, Kersten MJ, Fuchs M, Salmon F, Jäger U. Chimeric antigen receptor-T cell therapy: practical considerations for implementation in Europe. HemaSphere. (2018) 2:e18. doi: 10.1097/HES.0000000000000108

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.